Icon-facebook-1 X-twitter Linkedin Instagram Youtube

Viable Tissue Preservation and Governed Biospecimen Access—Built for Modern Translational Science

SpeciCare enables viable cryopreservation of tumor tissue and a quality-managed tissue stewardship workflow designed for downstream use cases like single-cell / single-nucleus sequencing, multi-omics, organoid/ALI models, and translational biomarker programs—while aligning with established biobanking quality systems and privacy/security expectations. (PMC)

Benefits of Cryopreservation

Preserve cellular viability for single-cell and functional assays

For workflows that depend on live cells (or intact nuclei), viable cryopreservation can maintain tumor heterogeneity and produce high-quality single-cell multi-omics outputs in multiple tumor types. (PMC)0

What that unlocks:
  • scRNA-seq / CITE-seq–style immune profiling (where appropriate)
  • Single-nucleus RNA-seq for frozen tissues when fresh dissociation is impractical (Nature)
  • Tumor ecosystem mapping at scale using standardized biobank workflows

Support organoid, ALI, and ex-vivo culture pipelines with less “fresh-tissue pressure”

Multiple studies demonstrate that slow-frozen or cryopreserved tumor tissues can remain viable for establishing 2D/3D cultures and related translational models, helping teams decouple collection logistics from experiment timing. (Nature)

Improve nucleic-acid integrity for omics and discovery programs

Frozen / appropriately preserved specimens are widely used to support higher-integrity DNA/RNA/protein endpoints—especially when paired with controlled preanalytics and SOP discipline. The NCI has published evidence-based practices for snap-freezing of post-surgical tissues for downstream DNA/RNA/protein and morphology analyses. (Cancer Treatment Division)
Genomic Analysis of Tumor Tissue

Tissue Licensing & Sales

Governed access models for biospecimens and derived materials

SpeciCare supports compliance-first access to biospecimens and derived materials (e.g., tissue aliquots, viable cell suspensions, nucleic acids, select derived models where available) through standard research contracting mechanisms.

Typical engagement models include:

  • Cost-recovery access fees (processing, storage, QC, fulfillment)
  • Study-based access (defined cohort + endpoints + release schedule)
  • Programmatic partnerships (longer-term translational alliances)
  • Derived-material access (where permitted and available)

How access is structured (practical + familiar to research offices)

Material Transfer Agreement (MTA) / Uniform templates

Transfers are commonly executed under an MTA (and sometimes the NIH UBMTA framework for nonprofit-to-nonprofit exchanges), defining permitted use, redistribution restrictions, publication norms, and IP terms. (Grants.gov)

Data use + privacy (HIPAA-aware handling)

Where human data is involved, sharing typically relies on de-identification methods and/or IRB/consent-aligned governance, consistent with HIPAA de-identification guidance and privacy rule principles for research disclosures. (HHS) (Implementation varies by institution; SpeciCare aligns to the requirements of your IRB/legal team and study design.)

Export / international collaboration safeguards (important 2025 update)

NIH issued a policy notice on enhancing security measures for human biospecimens (effective in late 2025), including documentation and restrictions around sharing NIH-supported biospecimens with “countries of concern” under narrow exceptions. If your project is NIH-funded or touches NIH-supported materials, this can affect cross-border transfer planning. (Grants.gov)

Regulatory boundary clarity (research vs. clinical use)

If materials are intended for implantation/transplantation/infusion into humans, U.S. FDA HCT/P regulations (21 CFR 1271) may be implicated. SpeciCare’s research access is structured for research use; clinical application pathways require separate regulatory consideration. (eCFR)

Typical engagement models include:

  • Cost-recovery access fees (processing, storage, QC, fulfillment)
  • Study-based access (defined cohort + endpoints + release schedule)
  • Programmatic partnerships (longer-term translational alliances)
  • Derived-material access (where permitted and available)

Peer Reviewed Papers / News

Viable cryopreservation preserves tumor heterogeneity for single-cell multi-omics

(Genome Medicine, 2021) — Demonstrates high-quality single-cell multi-omics from cryopreserved human cancers. (PMC)

Cryopreserved Tissue Biospecimens Offer Superior Quality for Whole-Genome Sequencing of Various Cancers Compared to Paired Formalin-Fixed Paraffin-Embedded Tissues – (International Journal of Molecular Science, November 2025) 

DNA Quantity and Quality Comparisons between Cryopreserved and FFPE Tumors from Matched Pan-Cancer Samples – The input of the quality of the biospecimen is known to impact the quality of the data output.(Current Oncology, April 2024)

 

Slow-frozen human tumor tissues remain viable for culture and profiling

(Communications Biology, 2022) — Reports viability across 2D/3D/ex vivo methods from slow-frozen solid tumor biopsies. (Nature)

Papillary Tumor of the Pineal Region Identified by DNA Methylation Leads to the Incidental Finding of Germline Mutation PTEN G132D Associated with PTEN Hamartoma Tumor Syndrome – (

A Case Report and Systematic Review:

Current Oncology, March 2025)

 

Hidden in the Noise: Low-Variant Allele Frequency Mutations and Their Impact on Precision Oncology –  FFPE creates considerably more “Noise” than Cryopreservation and hides low VAF’s. (Journal of Genome Biotechnology and Genetics, April 2026)

 

ISBER Best Practices (4th edition, 2018)

— Foundational repository governance/QMS guidance widely used in biobanking operations. (PMC)

Optimized nuclei extraction from small amounts of cryopreserved human tissue

(Scientific Reports, 2025) — Shows workable snRNA-seq prep from low-mass cryopreserved tissue inputs. (Nature)

Optimized nuclei isolation from long-term frozen pediatric glioma tissue

(Scientific Reports, 2025) — Addresses scarcity and feasibility for rare frozen clinical samples. (Nature)

Cryopreserved tumor tissues as a living tumor biobank resource for modeling & drug response

(2025, translational focus) — Highlights organoid/ALI and response testing utility from cryopreserved tissues. (ScienceDirect)